Phase I evaluation of sequential doxorubicin plus gemcitabine then ifosfamide plus paclitaxel plus cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract

Purpose: This phase I trial sought to evaluate the toxicity of and determin e the maximum-tolerated dose (MTD) for the two-drug regimen doxarubicin and gemcitabine (AG) followed by the three-drug regimen of ifosfamide, paclita xel, and cisplatin (ITP) in patients with unresectable or metastatic transi tional cell carcinoma. Patients and Methods: Patients received AG every other week for six cycles followed by ITP every 3 weeks for four cycles. Five AG dose levels were inv estigated, up to doxorubicin 50 mg/m(2) and gemcitabine 2,000 mg/m(2), to d etermine the MTD of the regimen. The dose and schedule of ITP were constant : ifosfamide 1,500 mg/m(2) (days 1 to 3); paclitaxel 200 mg/m(2) (day 1); a nd cisplatin 70 mg/m(2) (day 1). Granulocyte colony-stimulating factor was given between all cycles of therapy. Results: Fifteen patients enrolled onto this phase I trial, AG was well tol erated at all dose levels, with no grade 3 or 4 myelosuppression. Toxicity experienced with ITP included grade 3 and 4 granulocytopenia in four patien ts and grade 3 nausea/vomiting in three patients. No grade 3 and 4 neurotox icity was ob served. Eight of 14 assessable patients experienced a major re sponse to AG, including five of six patients treated at the two highest AG dose levels. After completion of AG-ITP, nine of 14 assessable patients had a major response (three complete responses and six partial responses). Conclusion: AG is a well-tolerated and active regimen. Sequential chemother apy with AG-ITP is also well tolerated, and phase II investigation at the h ighest dose level is ongoing. (C) 2000 by American Society of Clinical Onco logy.